INDERAL-LA CAPSULE (EXTENDED RELEASE)

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

PROPRANOLOL HYDROCHLORIDE

Disponible des:

PFIZER CANADA ULC

Codi ATC:

C07AA05

Designació comuna internacional (DCI):

PROPRANOLOL

Dosis:

120MG

formulario farmacéutico:

CAPSULE (EXTENDED RELEASE)

Composición:

PROPRANOLOL HYDROCHLORIDE 120MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

BETA-ADRENERGIC BLOCKING AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0101831001; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2022-05-31

Fitxa tècnica

_INDERAL-LA (propranolol hydrochloride) Product Monograph_
_ _
_Page 1 of 29_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
INDERAL
®
-LA
Propranolol Hydrochloride Extended-Release Capsules
Extended-Release Capsules, 60 mg, 80 mg, 120 mg and 160 mg, Oral
USP
Beta-Adrenergic Receptor Blocking Agent
Pfizer Canada ULC
Kirkland, Quebec H9J 2M5
Date of Initial Authorization:
SEP 21, 2010
Date of Revision:
June 16, 2021
Submission Control Number: 248972
®
Trademark AstraZeneca UK Limited
_ _
_INDERAL-LA (propranolol hydrochloride) Product Monograph _
_Page 2 of 29_
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.4
Administration...................................................................................................
6
4.5
Missed Dose
.....